4AB
AbbVie, Inc. · BX:4AB
240.89 CHF27.91 +13.10%
AbbVie, Inc. (BX:4AB) last traded at 240.89 CHF, up 13.10% on the day. Over the past year the stock is up 38.96%. Its 52-week range is 154.54 to 240.89. It is in the Health Technology sector (Pharmaceuticals: Major).
Key statistics
Open240.02
Day range240.00 – 240.89
52-week range154.54 – 240.89
Volume1.35 K
Average volume (10 days)281
Market cap (USD)521.11 B
P/E49.53
EPS (TTM) (USD)5.82
Dividend yield2.32%
Revenue (TTM) (USD)66.01 B
Employees57.00 K
Performance
+13.10%1 week
+13.10%1 month
+35.36%3 months
+53.94%6 months
+42.37%Year to date
+38.96%1 year
Technical rating
Strong buy
Daily summary of 11 oscillators and 15 moving averages. See every indicator
Analysts’ target
249.51 CHF
The average 1-year price target, +3.58% from the last price. See the forecast
Latest headlines
- The top 5 analyst questions from AbbVie’s Q3 earnings callStock Story · 01 Nov 2026
- Healthcare Earnings Scoreboard: 96% beat EPS estimates, 70% post Y/Y earnings growthSeeking Alpha · 31 Oct 2026
- Key facts: AbbVie, Inc. Q3 revenue $17.404B; Skyrizi approved; lutikizumab successTradingView · 31 Oct 2026
- ABBV Q3 deep dive: Immunology and neuroscience drive growth, pipeline progress continuesStock Story · 31 Oct 2026
- AbbVie Inc. Stock 12‑Month Price Target Raised to $291TradingView · 30 Oct 2026
- LLY, ABBV Stocks Hit All-Time High – Here’s What’s Driving Investor Enthusiasm TodayStocktwits · 30 Oct 2026
- AbbVie Stocks Rise 1.75% With Two Medicines Providing Nearly Half of RevenueGuruFocus · 30 Oct 2026
- What AbbVie (ABBV) Said on Its Q3 Earnings CallMarketBeat · 30 Oct 2026
Market data from TradingView’s public feed, delayed as the exchange requires. For study only, not investment advice.